Skip to main content

Advertisement

SpringerLink
Log in

Is personalized medicine finally arriving?

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

An Erratum to this article was published on 01 July 2008

This article has been updated

It's no gold rush, but dozens of players are emerging in personalized medicine, with biotechs, big and small, leading the way. Some big pharma companies and even payers remain skeptical, but economics aside, the real winners will be patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The emerging role of pharmacogenetics in biologics.
Figure 2: The RAS impass.
Figure 3: A winning curve.
Figure 4: The power of subtypes.

Change history

  • 08 July 2008

    In the version of this article initially published, Table 1 (page 510-511) contained two errors. In the entry for Agendia, the product Mammaprint was described as providing information on chemotherapy options for breast cancer patients. In fact Mammaprint is a prognostic test. In the entry for Genomic Health, the product Oncotype Dx was described as providing information on breast cancer recurrence. Oncotype DX also provides information on the response to chemotherapy.

References

  1. Chase, M. Payers aim to rein in specialty-drug spending. The Wall Street Journal, 20 March 2008, p B1.

  2. Russo, M.J. & Balekdjian, D. Nat. Biotechnol. 26, 173–182 (2008).

    Article  CAS  Google Scholar 

  3. Amado, R.G. et al. J. Clin. Oncol. 26, 1626–1634 (2008).

    Article  CAS  Google Scholar 

  4. Mallal, S. et al. N. Engl. J. Med. 358, 568–579 (2008).

    Article  Google Scholar 

  5. Shiffman, D. et al. J. Am. Coll. Cardiol. 51, 444–448 (2008).

    Article  CAS  Google Scholar 

  6. Winslow, R. Gene variant is said to be linked to heart attack and prevention. The Wall Street Journal, 22 Jan, 2008, p D3.

Download references

Author information

Authors and Affiliations

  1. Malorye Allison is a freelance writer based in Acton, Massachusetts.,

    Malorye Allison

Authors
  1. Malorye Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allison, M. Is personalized medicine finally arriving?. Nat Biotechnol 26, 509–517 (2008). https://doi.org/10.1038/nbt0508-509

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0508-509

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation